{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=24",
    "query": {
      "condition": "Effect of Drug",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 1898,
    "total_pages": 190,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:30:36.300Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04845646",
      "title": "DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "NAFLD"
      ],
      "interventions": [
        {
          "name": "ASC41",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Phenytoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gannex Pharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-03-16",
      "completion_date": "2021-06-10",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04845646"
    },
    {
      "nct_id": "NCT00279942",
      "title": "Effect of Revival Soy on Fibromyalgia Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Soy",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 50,
      "start_date": "2006-05",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2012-01-06",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00279942"
    },
    {
      "nct_id": "NCT07165808",
      "title": "Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nicotine Addiction"
      ],
      "interventions": [
        {
          "name": "Nicotine pouch: Low dose",
          "type": "OTHER"
        },
        {
          "name": "Nicotine pouch: High dose",
          "type": "OTHER"
        },
        {
          "name": "Low pH",
          "type": "OTHER"
        },
        {
          "name": "High pH",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "21 Years to 35 Years"
      },
      "enrollment_count": 84,
      "start_date": "2026-02-13",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07165808"
    },
    {
      "nct_id": "NCT04073017",
      "title": "Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "Enterade®",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-11-04",
      "completion_date": "2021-05-18",
      "has_results": false,
      "last_update_posted_date": "2021-05-21",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04073017"
    },
    {
      "nct_id": "NCT06491550",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD4144- Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part A",
          "type": "DRUG"
        },
        {
          "name": "AZD4144- Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part B",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin and Furosemide- Part C",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin, Furosemide, and AZD4144 Part C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 91,
      "start_date": "2024-07-15",
      "completion_date": "2025-06-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491550"
    },
    {
      "nct_id": "NCT07305779",
      "title": "A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SEP-380135",
          "type": "DRUG"
        },
        {
          "name": "Quinidine Gluconate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-03-07",
      "completion_date": "2025-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07305779"
    },
    {
      "nct_id": "NCT01053403",
      "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "MDMA Discontinuation Syndrome"
      ],
      "interventions": [
        {
          "name": "3,4-methylenedioxymethamphetamine or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Pacific Medical Center Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01053403"
    },
    {
      "nct_id": "NCT01289561",
      "title": "Combined Effects of Alcohol and Caffeine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol or Other Drugs Effects"
      ],
      "interventions": [
        {
          "name": "Alcohol + Caffeine Beverage",
          "type": "DRUG"
        },
        {
          "name": "Alcohol + Caffeine-placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2016-02-24",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01289561"
    },
    {
      "nct_id": "NCT01205503",
      "title": "Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mara Chambers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-24",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205503"
    },
    {
      "nct_id": "NCT03110770",
      "title": "VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Zika Virus",
        "Zika Virus Infection",
        "Virus Diseases",
        "Flavivirus Infections",
        "Flaviviral Diseases",
        "Flaviviridae Infections",
        "RNA Virus Infections"
      ],
      "interventions": [
        {
          "name": "VRC-ZKADNA090-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-PBSPLA043-00-VP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "15 Years to 35 Years"
      },
      "enrollment_count": 2428,
      "start_date": "2017-03-29",
      "completion_date": "2019-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-11-15T14:30:36.300Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Edinburg, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110770"
    }
  ]
}